Seres Therapeutics, Inc. (MCRB) Financials
Key financial figures for Seres Therapeutics, Inc. (Q2 2026).
Seres Therapeutics, Inc. reported revenue of $736.0 thousand for Q2 FY2026. Net income was $4.6 million, or $0.49 per share. Operating margin came to -2890.35%. Free cash flow for the period was -$22.4 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Seres Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $736K
- Net Income
- $5M
- EPS
- $0.47
- Total Assets
- $102M
- Operating Cash Flow
- -$22M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $736K | $5M | $0.49 | -2890.35% | -$22M |
| Q1 FY2026 | $358K | -$20M | -$2.08 | -5839.94% | -$16M |
| Q4 FY2025 | $438K | -$15M | -$1.76 | -4423.97% | -$15M |
| Q3 FY2025 | $351K | $8M | $0.94 | -6403.7% | $2M |
| Q2 FY2025 | $0 | -$20M | -$2.27 | -$13M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $789K | $6M | $0.64 | -11910.14% | $865K |
| FY2024 | $0 | -$147M | -$18.86 | -$149M | |
| FY2023 | $0 | -$114M | -$17.77 | -$125M |
Frequently asked questions
What was Seres Therapeutics, Inc.'s revenue last quarter?
Seres Therapeutics, Inc. reported revenue of $736.0 thousand for Q2 FY2026.
Is Seres Therapeutics, Inc. profitable?
Yes. Seres Therapeutics, Inc. reported net income of $4.6 million for Q2 FY2026, a net margin of 622.42% on revenue.
How has Seres Therapeutics, Inc.'s margin trended?
Operating margin was -2890.35% in Q2 FY2026. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Seres Therapeutics, Inc. generate?
Seres Therapeutics, Inc. generated free cash flow of -$22.4 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Seres Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.